Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
   PubMed Web of Science ®Google Scholar
• Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun 2021;41:1183–94.
   PubMed Web of Science ®Google Scholar
• Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 2018;834:188–96.
   PubMed Web of Science ®Google Scholar
• Widakowich C, de Azambuja E, Gil T, et al. Molecular targeted therapies in breast cancer: Where are we now? Int J Biochem Cell Biol 2007;39:1375–87.
   PubMed Web of Science ®Google Scholar
• Maennling AE, Tur MK, Niebert M, et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers (Basel) 2019;11:1826.
   PubMed Web of Science ®Google Scholar
• Habban Akhter M, Sateesh Madhav N, Ahmad J. Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. Artif Cells, Nanomedicine Biotechnol 2018;46:1188–98.
   PubMed Web of Science ®Google Scholar
• Pellat A, Vaquero J, Fouassier L. Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. Hepatology 2018;67:762–73.
   PubMed Web of Science ®Google Scholar
• Mitchell RA, Luwor RB, Burgess AW. Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics. Exp Cell Res 2018;371:1–19.
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997;70:722–6.
   PubMed Web of Science ®Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21–6.
   PubMed Web of Science ®Google Scholar
• Abdelgawad MA, Bakr RB, Alkhoja OA, Mohamed WR. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors. Bioorg Chem 2016;66:88–96.
   PubMed Web of Science ®Google Scholar
• Gaber AA, El-Morsy AM, Sherbiny FF, et al. Pharmacophore-linked pyrazolo[3,4-d]pyrimidines as EGFR-TK inhibitors: synthesis, anticancer evaluation, pharmacokinetics, and in silico mechanistic studies. Arch Pharm (Weinheim) 2021;e2100258.
   PubMed Web of Science ®Google Scholar
• Le T, Gerber DE. Newer-generation EGFR inhibitors in lung cancer: how are they best used? Cancers (Basel) 2019;11:366.
   PubMed Web of Science ®Google Scholar
• Mahapatra DK, Das D, Shivhare R. Substituted thiazole linked Murrayanine-Schiff’s base derivatives as potential anti-breast cancer candidates: future EGFR kinase inhibitors. Int J Pharm Sci Drug Res 2017;9:139–44.
   Google Scholar
• Zhang H. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer. Drug Des Devel Ther 2016;10:3867–72.
   PubMed Web of Science ®Google Scholar
• Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR inhibitors: critical updates. Mini-Reviews Med Chem 2016;16:1134–66.
   PubMed Web of Science ®Google Scholar
• Ercan D, Choi HG, Yun C-H, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 2015;21:3913–23.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665–70.
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012;13:528–38.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076–83.
   PubMed Web of Science ®Google Scholar
• Kim Y, Lee S-H, Ahn JS, et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat 2019;51:502–9.
   PubMed Web of Science ®Google Scholar
• Tan C-S, Kumarakulasinghe NB, Huang Y-Q, et al. Third generation EGFR TKIs: current data and future directions. Mol Cancer 2018;17:1–14.
   PubMed Web of Science ®Google Scholar
• Hassan RA, Emam SH, Hwang D, et al. Design, synthesis and evaluation of anticancer activity of new pyrazoline derivatives by down-regulation of VEGF: molecular docking and apoptosis inducing activity. Bioorg Chem 2022;118:105487.
   PubMed Web of Science ®Google Scholar
• El-Dash Y, Elzayat E, Abdou AM, Hassan RA. Novel thienopyrimidine-aminothiazole hybrids: design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. Bioorg Chem 2021;114:105137.
   PubMed Web of Science ®Google Scholar
• Nemr MTM, Sonousi A, Marzouk AA. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: molecular docking and apoptosis inducing activity. Bioorg Chem 2020;105:104446.
   PubMed Web of Science ®Google Scholar
• Halim PA, Hassan RA, Mohamed KO, et al. Synthesis and biological evaluation of halogenated phenoxychalcones and their corresponding pyrazolines as cytotoxic agents in human breast cancer. J Enzyme Inhib Med Chem 2022;37:189–201.
   PubMed Web of Science ®Google Scholar
• Hassan RA, Hamed MIA, Abdou AM, El-dash Y. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking. Bioorg Chem 2022;125:105861.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015;21:3924–33.
   PubMed Web of Science ®Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560–2.
   PubMed Web of Science ®Google Scholar
• Yan G, Zekarias BL, Li X, et al. Divergent 2-chloroquinazolin-4(3H)-one rearrangement: twisted-cyclic guanidine formation or ring-fused N-acylguanidines via a domino process. Chem - A Eur J 2020;26:2486–92.
   PubMed Web of Science ®Google Scholar
• Kumari S, Chowdhury J, Sikka M, et al. Identification of potent cholecystokinin-B receptor antagonists: synthesis, molecular modeling and anti-cancer activity against pancreatic cancer cells. Medchemcomm 2017;8:1561–74.
   PubMed Web of Science ®Google Scholar
• Alanazi AM, Abdel-Aziz AA-M, Shawer TZ, et al. Synthesis, antitumor and antimicrobial activity of some new 6-methyl-3-phenyl-4(3H)-quinazolinone analogues: in silico studies. J Enzyme Inhib Med Chem 2016;31:721–35.
   PubMed Web of Science ®Google Scholar
• El-Azab AS, Abdel-Hamide SG, Sayed-Ahmed MM, et al. Novel 4(3H)-quinazolinone analogs: synthesis and anticonvulsant activity. Med Chem Res 2013;22:2815–27.
   Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107–12.
   PubMed Web of Science ®Google Scholar
• Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91–109.
   Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813–23.
   PubMed Web of Science ®Google Scholar
• Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589–601.
   PubMed Web of Science ®Google Scholar
• Naruse I, Ohmori T, Ao Y, et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002;98:310–5.
   PubMed Web of Science ®Google Scholar
• Tolba MF, Esmat A, Al-Abd AM, et al. Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells. IUBMB Life 2013;65:716–29.
   PubMed Web of Science ®Google Scholar
• Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J Vis Exp 2011;50:e2597.
   Google Scholar
• Maher M, Kassab AE, Zaher AF, Mahmoud Z. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. J Enzyme Inhib Med Chem 2019;34:532–46.
   PubMed Web of Science ®Google Scholar
• Shawali AS, Hassaneen HM, Shurrab NK. A new convenient synthesis of 2,4-disubstituted-1,2,4-triazolo[1,5-a]quinazolin-5(4 H)-ones. J Heterocycl Chem 2008;45:1825–9.
   Web of Science ®Google Scholar
• Tavakol H, Farrokhpour H. DFT and MP2 study of low barrier proton transfer in hydrazide schiff base tautomers via water bridges and in the gas. J Mol Model 2013;19:3471–9.
   PubMed Web of Science ®Google Scholar
• Sakr A, Rezq S, Ibrahim SM, et al. Design and synthesis of novel quinazolinones conjugated ibuprofen indole acetamide or thioacetohydrazide as selective COX 2 inhibitors: anti-inflammatory, analgesic and anticancer activities. J Enzyme Inhib Med Chem 2021;36:1810–28.
   PubMed Web of Science ®Google Scholar
• El-Sayed S, Metwally K, El-Shanawani AA, Abdel-Aziz LM, et al. Synthesis and anticancer activity of novel quinazolinone-based rhodanines. Chem Cent J 2017;11:102.
   PubMedGoogle Scholar
• Matson JP, Cook JG. Cell cycle proliferation decisions: the impact of single cell analyses. FEBS J 2017;284:362–75.
   PubMed Web of Science ®Google Scholar
• Gorczyca W. Cytometric analyses to distinguish death processes. Endocr Relat Cancer 1999;6:17–9.
   PubMed Web of Science ®Google Scholar
• Utsuro M. Neutron spin interference visibility in tunneling transmission through magnetic resonators. Phys B Condens Matter 2005;358:232–46.
   Web of Science ®Google Scholar
• Gong L, Tang Y, An R, et al. RTN1-C mediates cerebral ischemia/reperfusion injury via ER stress and mitochondria-associated apoptosis pathways. Cell Death Dis 2017;8:e3080.
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265–72.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE), 2020.09 Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7. 2022.
   Google Scholar
• Cavallo G, Metrangolo P, Milani R, et al. The halogen bond. Chem Rev 2016;116:2478–601.
   PubMed Web of Science ®Google Scholar